Literature DB >> 8221671

Sequence-specific interaction of a conformational domain of p53 with DNA.

R Srinivasan1, J A Roth, S A Maxwell.   

Abstract

Mutations within a conserved "conformational" domain of the p53 protein have frequently been observed in a wide variety of human cancers. A hybrid protein containing the wild-type conformational domain of p53 fused to protein A bound to calf thymus DNA and a specific p53 DNA-binding motif. Hybrid proteins containing mutations in p53 bound to DNA less efficiently than wild-type hybrid protein. In addition, competition experiments showed that mutated p53 DNA-binding motif failed to interact with p53 hybrid proteins. The DNA-binding activity of wild-type p53 hybrid protein was inhibited by the metal chelator 1,10-phenanthroline. These results demonstrate that DNA-binding activity resides in the conformational domain of p53, providing a structural model for disruption of DNA binding by mutation. Furthermore, metal ions may regulate binding of p53 to DNA by modulating its conformation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221671

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  p53 domains: structure, oligomerization, and transformation.

Authors:  P Wang; M Reed; Y Wang; G Mayr; J E Stenger; M E Anderson; J F Schwedes; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

3.  Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene.

Authors:  T Seta; F Imazeki; O Yokosuka; H Saisho; T Suzuki; Y Koide; K Isono
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

Review 4.  Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment.

Authors:  J A Roth
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.